CAMP4 Therapeutics

Contributing Author

Recent Articles by CAMP4 Therapeutics

Sep-10	CAMP4 Therapeutics Receives Authorization in the United Kingdom for Phase 1/2 Human Clinical Trial of CMP-002 in Patients with SYNGAP1-Related Disorder CAMP GlobeNewswire
Sep-08	CAMP4 Therapeutics to Host Virtual Analyst Day to Discuss CMP-002 for the Treatment of SYNGAP1-Related Disorder on September 28, 2026 CAMP GlobeNewswire
Sep-01	CAMP4 to Participate in Upcoming Investor Conferences CAMP GlobeNewswire
Aug-13	CAMP4 Reports Second Quarter 2026 Financial Results and Corporate Highlights CAMP CAMP +20.89% GlobeNewswire
Aug-04	CAMP4 Therapeutics Announces Second Closing of $100 Million Private Placement CAMP GlobeNewswire
Jul-27	CAMP4 Therapeutics Secures Australian Regulatory Clearance to Initiate First-in-Human Clinical Trial of CMP-002 in Patients With SYNGAP1-Related Disorder CAMP +8.23% GlobeNewswire
Jul-17	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMP CAMP -10.51% GlobeNewswire
Jun-19	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
May-21	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
May-14	CAMP4 Therapeutics to Present New Preclinical Data Demonstrating CMP-002 Improves Seizure Threshold and Severity in a Model of SYNGAP1-Related Disorder CAMP GlobeNewswire
May-07	CAMP4 Reports First Quarter 2026 Financial Results and Corporate Highlights CAMP +6.90% GlobeNewswire
Apr-28	CAMP4 Therapeutics Preprints Pioneering Study on Regulatory RNA Profiling and Gene Upregulation CAMP GlobeNewswire
Apr-17	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
Mar-24	CAMP4 Appoints Michael MacLean to its Board of Directors CAMP GlobeNewswire
Mar-06	CAMP4 to Participate in Upcoming Investor Conferences CAMP -8.50% CAMP +49.40% GlobeNewswire
Mar-05	CAMP4 Reports Full Year 2025 Financial Results and Corporate Highlights CAMP +12.50% GlobeNewswire
Feb-20	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
Jan-16	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMP CAMP -21.00% GlobeNewswire
Jan-06	CAMP4 to Present at the 44th Annual J.P. Morgan Healthcare Conference CAMP GlobeNewswire
Dec-18	CAMP4 Announces Pricing of $30.0 Million Underwritten Offering of Common Stock CAMP -12.90% GlobeNewswire
Dec-18	CAMP4 and GSK Enter Strategic Collaboration to Advance RNA-Based Therapeutic Discoveries CAMP -12.90% GlobeNewswire
Dec-12	CAMP4 Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) CAMP +7.99% GlobeNewswire
Nov-14	CAMP4 Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) CAMP GlobeNewswire
Nov-06	CAMP4 Reports Third Quarter 2025 Financial Results and Corporate Highlights CAMP +6.97% GlobeNewswire
Oct-01	CAMP4 Therapeutics Initiates GLP Toxicology Studies for CMP-SYNGAP-01 CAMP GlobeNewswire
Sep-10	CAMP4 Announces an Oversubscribed Private Placement of up to $100 Million to Advance First-in-Class Treatment for SYNGAP1-Related Disorders CAMP +40.20% GlobeNewswire
Aug-14	CAMP4 Reports Second Quarter 2025 Financial Results and Corporate Highlights CAMP +6.16% CAMP +7.74% GlobeNewswire
May-16	CAMP4 Presents Translational Data from SYNGAP1-Related Disorders Program Showcasing Increased Protein in Non-Human Primates and Reviews Preclinical and Detailed Single Ascending Dose Safety Data from Urea Cycle Disorders Program at the 28th American Society of Gene and Cell Therapy Annual Meeting CAMP +9.52% GlobeNewswire
May-13	CAMP4 Reports First Quarter 2025 Financial Results and Corporate Highlights CAMP CAMP -7.92% GlobeNewswire

CAMP4 Therapeutics

Recent Articles by CAMP4 Therapeutics

Upgrade your Finviz experience